Showing results (1741-1750 of 3,638) with videos related to
Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|June 22, 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerL Gianni, S Delaloge, E Ciruelos, et al.Breast (Edinburgh, Scotland)|June 25, 2026
Autonomous motivation and adherence intention in long-term breast cancer treatment: a self-determination theory modelIrène Georgescu, Elodie Gigout, Étienne Minvielle, et al.Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.Breast (Edinburgh, Scotland)|July 7, 2026
Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysisAndrea Carlini, Flavia Foca, Marianna Sirico, et al.Breast (Edinburgh, Scotland)|July 24, 2026
Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trialMengxue Qiu, Hui Dai, Tao Zhu, et al.Breast (Edinburgh, Scotland)|July 18, 2026
Latin American consensus on the medical oncologic management of early-stage HR+/HER2- breast cancer: Addressing regional disparities in Spanish-speaking countriesDenis U Landaverde, Fernando Petracci, Angela Grano de Oro, et al.Breast (Edinburgh, Scotland)|July 22, 2026
Eribulin for patients with metastatic breast cancer in England 2012-2021: Survival outcomes and 30-day mortalityZhe Wang, Lorna Roden, Rebecca Watters, et al.Breast (Edinburgh, Scotland)|July 23, 2026
[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trialRosa Di Micco, Edoardo Botteri, Carla Canevari, et al.Breast (Edinburgh, Scotland)|August 22, 2026
Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trialTejal D Durgekar, Shyamili Goutham, Xi Zhang, et al.Breast (Edinburgh, Scotland)|August 27, 2026
Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancerJingkun Li, Xinhao Han, Yan Zhuang, et al.Pageof 364